| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-Bacterial Agents | 116 | 2024 | 2397 | 16.620 |
Why?
|
| Polymyxin B | 27 | 2024 | 45 | 10.620 |
Why?
|
| Pseudomonas aeruginosa | 39 | 2023 | 166 | 9.230 |
Why?
|
| Acinetobacter baumannii | 16 | 2024 | 36 | 8.020 |
Why?
|
| Microbial Sensitivity Tests | 74 | 2024 | 782 | 7.560 |
Why?
|
| Pseudomonas Infections | 23 | 2023 | 116 | 7.020 |
Why?
|
| Acinetobacter Infections | 11 | 2024 | 25 | 6.250 |
Why?
|
| Cephalosporins | 20 | 2024 | 138 | 5.700 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 29 | 2024 | 133 | 5.610 |
Why?
|
| Klebsiella pneumoniae | 16 | 2022 | 71 | 4.620 |
Why?
|
| Drug Resistance, Bacterial | 22 | 2017 | 361 | 4.070 |
Why?
|
| Bacteremia | 13 | 2022 | 404 | 3.840 |
Why?
|
| Anti-Infective Agents | 18 | 2022 | 266 | 3.640 |
Why?
|
| Carbapenems | 6 | 2024 | 35 | 3.340 |
Why?
|
| beta-Lactamase Inhibitors | 9 | 2023 | 55 | 3.230 |
Why?
|
| Minocycline | 6 | 2022 | 36 | 3.130 |
Why?
|
| Ceftazidime | 6 | 2024 | 41 | 2.930 |
Why?
|
| Klebsiella Infections | 8 | 2022 | 51 | 2.870 |
Why?
|
| Polymyxins | 8 | 2023 | 14 | 2.810 |
Why?
|
| Gram-Negative Bacterial Infections | 15 | 2019 | 86 | 2.760 |
Why?
|
| beta-Lactamases | 16 | 2023 | 192 | 2.640 |
Why?
|
| Models, Biological | 21 | 2018 | 1444 | 2.610 |
Why?
|
| Colistin | 9 | 2019 | 30 | 2.510 |
Why?
|
| beta-Lactam Resistance | 8 | 2019 | 46 | 2.390 |
Why?
|
| Azabicyclo Compounds | 7 | 2024 | 16 | 2.320 |
Why?
|
| Aminoglycosides | 9 | 2023 | 44 | 2.230 |
Why?
|
| beta-Lactams | 9 | 2020 | 50 | 2.180 |
Why?
|
| Pneumonia, Bacterial | 8 | 2015 | 76 | 2.150 |
Why?
|
| Amikacin | 7 | 2023 | 23 | 2.080 |
Why?
|
| Gram-Negative Bacteria | 10 | 2023 | 67 | 2.050 |
Why?
|
| Tandem Mass Spectrometry | 10 | 2024 | 227 | 1.880 |
Why?
|
| Chromatography, Liquid | 8 | 2020 | 191 | 1.770 |
Why?
|
| Drug Combinations | 8 | 2024 | 269 | 1.630 |
Why?
|
| Thienamycins | 7 | 2017 | 14 | 1.570 |
Why?
|
| Vancomycin | 6 | 2020 | 218 | 1.530 |
Why?
|
| Bacterial Proteins | 10 | 2022 | 878 | 1.510 |
Why?
|
| Bacterial Infections | 7 | 2019 | 305 | 1.510 |
Why?
|
| Staphylococcus aureus | 8 | 2024 | 455 | 1.500 |
Why?
|
| Kidney Tubules, Proximal | 4 | 2024 | 109 | 1.470 |
Why?
|
| Kidney | 10 | 2023 | 1335 | 1.430 |
Why?
|
| Acute Kidney Injury | 5 | 2024 | 614 | 1.390 |
Why?
|
| Renal Insufficiency | 4 | 2016 | 234 | 1.340 |
Why?
|
| Humans | 134 | 2024 | 123305 | 1.320 |
Why?
|
| Fluoroquinolones | 7 | 2011 | 92 | 1.290 |
Why?
|
| Escherichia coli | 8 | 2019 | 983 | 1.280 |
Why?
|
| Ceftriaxone | 4 | 2020 | 68 | 1.250 |
Why?
|
| Sepsis | 3 | 2023 | 476 | 1.230 |
Why?
|
| Low Density Lipoprotein Receptor-Related Protein-2 | 3 | 2024 | 14 | 1.150 |
Why?
|
| Models, Theoretical | 11 | 2016 | 356 | 1.130 |
Why?
|
| Pneumonia, Ventilator-Associated | 2 | 2021 | 41 | 1.100 |
Why?
|
| Culture Media | 3 | 2024 | 183 | 1.060 |
Why?
|
| Rats, Sprague-Dawley | 12 | 2023 | 1217 | 1.040 |
Why?
|
| Levofloxacin | 6 | 2017 | 45 | 1.030 |
Why?
|
| Ofloxacin | 7 | 2012 | 32 | 1.000 |
Why?
|
| Models, Statistical | 6 | 2014 | 472 | 0.970 |
Why?
|
| Microbial Viability | 3 | 2011 | 42 | 0.960 |
Why?
|
| Cerebral Ventriculitis | 1 | 2024 | 15 | 0.950 |
Why?
|
| Licensure, Pharmacy | 1 | 2024 | 1 | 0.950 |
Why?
|
| Creatinine | 8 | 2023 | 381 | 0.930 |
Why?
|
| Bacteria | 5 | 2021 | 482 | 0.910 |
Why?
|
| Pharmaceutical Preparations | 3 | 2021 | 79 | 0.910 |
Why?
|
| Dose-Response Relationship, Drug | 17 | 2020 | 1686 | 0.900 |
Why?
|
| Pharmacists | 1 | 2024 | 83 | 0.880 |
Why?
|
| Animals | 43 | 2024 | 33817 | 0.880 |
Why?
|
| Education, Pharmacy | 1 | 2024 | 54 | 0.870 |
Why?
|
| Students, Pharmacy | 1 | 2024 | 63 | 0.860 |
Why?
|
| Cross Infection | 7 | 2017 | 330 | 0.850 |
Why?
|
| Moths | 1 | 2023 | 22 | 0.840 |
Why?
|
| Middle Aged | 39 | 2024 | 26075 | 0.830 |
Why?
|
| Female | 62 | 2024 | 65618 | 0.820 |
Why?
|
| Imipenem | 2 | 2012 | 9 | 0.800 |
Why?
|
| Plasma | 3 | 2015 | 96 | 0.790 |
Why?
|
| Pharmacokinetics | 3 | 2006 | 16 | 0.760 |
Why?
|
| Piperacillin | 6 | 2019 | 13 | 0.760 |
Why?
|
| Iron | 1 | 2024 | 262 | 0.760 |
Why?
|
| Educational Measurement | 1 | 2024 | 324 | 0.760 |
Why?
|
| Male | 57 | 2024 | 60282 | 0.750 |
Why?
|
| Aged | 32 | 2024 | 19173 | 0.740 |
Why?
|
| Lactams | 1 | 2021 | 14 | 0.730 |
Why?
|
| Area Under Curve | 8 | 2024 | 314 | 0.730 |
Why?
|
| Transitional Care | 1 | 2020 | 18 | 0.720 |
Why?
|
| Rats | 13 | 2023 | 3664 | 0.710 |
Why?
|
| Quinolines | 4 | 2011 | 96 | 0.680 |
Why?
|
| Epithelial Cells | 2 | 2014 | 899 | 0.670 |
Why?
|
| Drug Therapy, Combination | 10 | 2017 | 1142 | 0.670 |
Why?
|
| Colony Count, Microbial | 10 | 2009 | 89 | 0.650 |
Why?
|
| Cystic Fibrosis | 1 | 2021 | 257 | 0.630 |
Why?
|
| Drug Monitoring | 5 | 2020 | 156 | 0.630 |
Why?
|
| Enterobacteriaceae | 1 | 2019 | 35 | 0.630 |
Why?
|
| Blood Proteins | 2 | 2017 | 116 | 0.610 |
Why?
|
| Lung | 7 | 2018 | 1466 | 0.610 |
Why?
|
| Aged, 80 and over | 15 | 2019 | 6387 | 0.610 |
Why?
|
| Hospitals, University | 4 | 2012 | 96 | 0.600 |
Why?
|
| Hepatitis A Virus Cellular Receptor 1 | 1 | 2017 | 2 | 0.590 |
Why?
|
| Infusions, Intravenous | 10 | 2020 | 537 | 0.590 |
Why?
|
| Administration, Intravenous | 5 | 2022 | 143 | 0.580 |
Why?
|
| Time Factors | 16 | 2014 | 6228 | 0.580 |
Why?
|
| Apoptosis | 1 | 2024 | 1787 | 0.570 |
Why?
|
| Drug Utilization | 3 | 2016 | 159 | 0.570 |
Why?
|
| Outpatients | 3 | 2014 | 254 | 0.560 |
Why?
|
| Neutropenia | 2 | 2017 | 202 | 0.550 |
Why?
|
| Gentamicins | 4 | 2017 | 95 | 0.540 |
Why?
|
| Adult | 29 | 2024 | 29087 | 0.540 |
Why?
|
| Disease Susceptibility | 1 | 2018 | 298 | 0.530 |
Why?
|
| Pneumonia | 2 | 2017 | 325 | 0.530 |
Why?
|
| Mice | 19 | 2024 | 17546 | 0.510 |
Why?
|
| Virulence | 4 | 2022 | 261 | 0.510 |
Why?
|
| Gram-Positive Bacterial Infections | 5 | 2012 | 76 | 0.510 |
Why?
|
| Serum | 5 | 2014 | 46 | 0.490 |
Why?
|
| Immunity, Innate | 1 | 2018 | 372 | 0.490 |
Why?
|
| Antimicrobial Stewardship | 1 | 2016 | 83 | 0.470 |
Why?
|
| APACHE | 4 | 2021 | 52 | 0.460 |
Why?
|
| Disease Models, Animal | 10 | 2020 | 4289 | 0.460 |
Why?
|
| Texas | 9 | 2024 | 3568 | 0.460 |
Why?
|
| Hyperglycemia | 1 | 2015 | 222 | 0.440 |
Why?
|
| Urinary Tract Infections | 2 | 2016 | 294 | 0.440 |
Why?
|
| Intensive Care Units | 5 | 2024 | 483 | 0.430 |
Why?
|
| Half-Life | 4 | 2023 | 156 | 0.430 |
Why?
|
| Survival Analysis | 5 | 2018 | 1473 | 0.430 |
Why?
|
| Aza Compounds | 2 | 2011 | 15 | 0.420 |
Why?
|
| Liposomes | 1 | 2013 | 169 | 0.410 |
Why?
|
| Body Fluids | 1 | 2013 | 47 | 0.410 |
Why?
|
| Kidney Tubular Necrosis, Acute | 1 | 2012 | 8 | 0.410 |
Why?
|
| Enterococcus faecalis | 3 | 2022 | 45 | 0.410 |
Why?
|
| Mutation | 6 | 2012 | 5768 | 0.400 |
Why?
|
| Computer Simulation | 6 | 2018 | 630 | 0.400 |
Why?
|
| HIV Infections | 2 | 2023 | 1855 | 0.390 |
Why?
|
| Retrospective Studies | 15 | 2024 | 16066 | 0.380 |
Why?
|
| Cell Line | 4 | 2024 | 2771 | 0.380 |
Why?
|
| Cefazolin | 2 | 2024 | 20 | 0.380 |
Why?
|
| Protein Binding | 4 | 2019 | 1741 | 0.380 |
Why?
|
| Cell Survival | 3 | 2024 | 808 | 0.370 |
Why?
|
| Escherichia coli Infections | 2 | 2012 | 190 | 0.370 |
Why?
|
| Aerosols | 1 | 2011 | 65 | 0.370 |
Why?
|
| Treatment Outcome | 13 | 2018 | 12168 | 0.370 |
Why?
|
| Staphylococcal Infections | 2 | 2024 | 552 | 0.360 |
Why?
|
| Prospective Studies | 11 | 2018 | 6032 | 0.360 |
Why?
|
| Rec A Recombinases | 1 | 2010 | 26 | 0.360 |
Why?
|
| Critical Illness | 3 | 2020 | 591 | 0.350 |
Why?
|
| Drug Synergism | 4 | 2019 | 239 | 0.350 |
Why?
|
| Sodium Chloride | 1 | 2010 | 95 | 0.350 |
Why?
|
| Chromatography, High Pressure Liquid | 5 | 2014 | 338 | 0.340 |
Why?
|
| Endocarditis, Bacterial | 3 | 2017 | 129 | 0.340 |
Why?
|
| Larva | 2 | 2023 | 247 | 0.340 |
Why?
|
| Polymerase Chain Reaction | 6 | 2012 | 1584 | 0.340 |
Why?
|
| Doxycycline | 2 | 2022 | 115 | 0.320 |
Why?
|
| Neutrophils | 1 | 2011 | 373 | 0.320 |
Why?
|
| Kinetics | 5 | 2017 | 1314 | 0.320 |
Why?
|
| ADP Ribose Transferases | 1 | 2008 | 18 | 0.320 |
Why?
|
| Stenotrophomonas maltophilia | 1 | 2008 | 8 | 0.310 |
Why?
|
| Cohort Studies | 7 | 2024 | 4709 | 0.310 |
Why?
|
| Selection, Genetic | 1 | 2009 | 155 | 0.310 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2008 | 42 | 0.310 |
Why?
|
| Bacterial Load | 3 | 2013 | 29 | 0.300 |
Why?
|
| Bacterial Adhesion | 1 | 2008 | 107 | 0.300 |
Why?
|
| Clarithromycin | 1 | 2008 | 124 | 0.300 |
Why?
|
| Gram-Negative Aerobic Bacteria | 1 | 2007 | 1 | 0.300 |
Why?
|
| Monte Carlo Method | 7 | 2014 | 92 | 0.300 |
Why?
|
| Biofilms | 1 | 2008 | 91 | 0.300 |
Why?
|
| Transcription Factors | 1 | 2018 | 2587 | 0.290 |
Why?
|
| Rifampin | 1 | 2008 | 126 | 0.290 |
Why?
|
| Drug Resistance, Microbial | 5 | 2011 | 192 | 0.290 |
Why?
|
| Risk Factors | 10 | 2019 | 10042 | 0.290 |
Why?
|
| Bacterial Toxins | 1 | 2008 | 175 | 0.290 |
Why?
|
| Tetracyclines | 2 | 2017 | 14 | 0.290 |
Why?
|
| Streptococcus pneumoniae | 2 | 2006 | 372 | 0.280 |
Why?
|
| Prevalence | 6 | 2024 | 2407 | 0.280 |
Why?
|
| Energy Metabolism | 1 | 2012 | 770 | 0.270 |
Why?
|
| Injections, Subcutaneous | 2 | 2020 | 126 | 0.270 |
Why?
|
| Meningitis, Bacterial | 1 | 2006 | 94 | 0.250 |
Why?
|
| DNA Topoisomerase IV | 3 | 2012 | 10 | 0.250 |
Why?
|
| DNA Gyrase | 3 | 2012 | 21 | 0.250 |
Why?
|
| Risk Assessment | 4 | 2016 | 3337 | 0.250 |
Why?
|
| Antiviral Agents | 2 | 2015 | 744 | 0.240 |
Why?
|
| Tobramycin | 1 | 2004 | 23 | 0.240 |
Why?
|
| Reproducibility of Results | 5 | 2014 | 2844 | 0.240 |
Why?
|
| Biomarkers | 4 | 2018 | 2948 | 0.240 |
Why?
|
| Liver | 3 | 2021 | 1738 | 0.230 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2024 | 61 | 0.230 |
Why?
|
| Flavonoids | 3 | 2012 | 78 | 0.220 |
Why?
|
| Immunocompromised Host | 3 | 2017 | 295 | 0.220 |
Why?
|
| Ribavirin | 1 | 2003 | 79 | 0.220 |
Why?
|
| Glomerular Filtration Rate | 2 | 2018 | 481 | 0.210 |
Why?
|
| Drug Costs | 2 | 2016 | 60 | 0.210 |
Why?
|
| Iron Chelating Agents | 1 | 2023 | 14 | 0.210 |
Why?
|
| Injections, Intravenous | 3 | 2015 | 252 | 0.210 |
Why?
|
| Communicable Diseases | 3 | 2010 | 161 | 0.210 |
Why?
|
| Multilocus Sequence Typing | 1 | 2022 | 56 | 0.210 |
Why?
|
| Models, Animal | 2 | 2023 | 464 | 0.200 |
Why?
|
| Tissue Distribution | 3 | 2015 | 382 | 0.200 |
Why?
|
| Oils, Volatile | 1 | 2022 | 3 | 0.200 |
Why?
|
| Phytochemicals | 1 | 2021 | 8 | 0.190 |
Why?
|
| Metabolic Clearance Rate | 3 | 2015 | 142 | 0.190 |
Why?
|
| Virginiamycin | 1 | 2001 | 3 | 0.180 |
Why?
|
| Research Design | 2 | 2013 | 679 | 0.180 |
Why?
|
| Phenols | 1 | 2021 | 58 | 0.180 |
Why?
|
| Decision Making | 1 | 2006 | 652 | 0.180 |
Why?
|
| Mice, Inbred BALB C | 3 | 2018 | 1003 | 0.180 |
Why?
|
| Population Surveillance | 1 | 2003 | 383 | 0.180 |
Why?
|
| Young Adult | 6 | 2016 | 8871 | 0.170 |
Why?
|
| Home Infusion Therapy | 1 | 1999 | 6 | 0.170 |
Why?
|
| Nanoparticles | 1 | 2022 | 231 | 0.160 |
Why?
|
| Body Weight | 2 | 2020 | 1002 | 0.160 |
Why?
|
| Quinolones | 4 | 2017 | 54 | 0.160 |
Why?
|
| Microsomes, Liver | 3 | 2009 | 85 | 0.160 |
Why?
|
| Intestine, Small | 1 | 2021 | 302 | 0.160 |
Why?
|
| Penicillanic Acid | 2 | 2009 | 9 | 0.160 |
Why?
|
| Oxidative Stress | 1 | 2024 | 795 | 0.160 |
Why?
|
| Proteomics | 1 | 2022 | 479 | 0.150 |
Why?
|
| Adolescent | 7 | 2016 | 19132 | 0.150 |
Why?
|
| Cytochrome b Group | 1 | 2018 | 5 | 0.150 |
Why?
|
| Lepidoptera | 1 | 2018 | 4 | 0.150 |
Why?
|
| Microsomes | 2 | 2009 | 55 | 0.150 |
Why?
|
| Intestinal Mucosa | 3 | 2009 | 771 | 0.150 |
Why?
|
| United States | 4 | 2018 | 10667 | 0.150 |
Why?
|
| Clinical Trials as Topic | 4 | 2014 | 1084 | 0.150 |
Why?
|
| Asia | 1 | 2018 | 107 | 0.150 |
Why?
|
| Tularemia | 1 | 2017 | 13 | 0.140 |
Why?
|
| Francisella tularensis | 1 | 2017 | 15 | 0.140 |
Why?
|
| Maleates | 1 | 2017 | 14 | 0.140 |
Why?
|
| Microdialysis | 1 | 2017 | 56 | 0.140 |
Why?
|
| Arginine | 1 | 2019 | 304 | 0.140 |
Why?
|
| Daptomycin | 2 | 2017 | 14 | 0.140 |
Why?
|
| Nicotinic Antagonists | 1 | 2016 | 9 | 0.130 |
Why?
|
| Carbimazole | 1 | 2016 | 1 | 0.130 |
Why?
|
| Methimazole | 1 | 2016 | 6 | 0.130 |
Why?
|
| Antithyroid Agents | 1 | 2016 | 4 | 0.130 |
Why?
|
| Sucrose | 1 | 2016 | 39 | 0.130 |
Why?
|
| Agranulocytosis | 1 | 2016 | 14 | 0.130 |
Why?
|
| Endocarditis | 1 | 2017 | 101 | 0.130 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 2007 | 313 | 0.130 |
Why?
|
| HLA-B Antigens | 1 | 2016 | 28 | 0.130 |
Why?
|
| Nicotinic Agonists | 1 | 2016 | 44 | 0.130 |
Why?
|
| Comorbidity | 1 | 2021 | 1498 | 0.130 |
Why?
|
| Organophosphonates | 1 | 2015 | 19 | 0.130 |
Why?
|
| Cytosine | 1 | 2015 | 56 | 0.130 |
Why?
|
| Adenoviridae Infections | 1 | 2015 | 70 | 0.120 |
Why?
|
| Gene Expression | 2 | 2018 | 1565 | 0.120 |
Why?
|
| Population | 2 | 2006 | 21 | 0.120 |
Why?
|
| Food Preferences | 1 | 2016 | 117 | 0.120 |
Why?
|
| Aspergillosis | 2 | 2006 | 43 | 0.120 |
Why?
|
| Drug Administration Schedule | 2 | 2012 | 725 | 0.120 |
Why?
|
| Lung Diseases, Fungal | 2 | 2006 | 32 | 0.120 |
Why?
|
| Cystitis | 1 | 2015 | 50 | 0.120 |
Why?
|
| Singapore | 3 | 2010 | 16 | 0.120 |
Why?
|
| Genomics | 1 | 2022 | 1474 | 0.120 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 300 | 0.120 |
Why?
|
| Respiratory Tract Infections | 1 | 2017 | 263 | 0.120 |
Why?
|
| Biological Transport, Active | 1 | 2014 | 87 | 0.110 |
Why?
|
| Arginine Vasopressin | 1 | 2014 | 28 | 0.110 |
Why?
|
| Urine | 1 | 2014 | 89 | 0.110 |
Why?
|
| Acclimatization | 1 | 2013 | 15 | 0.110 |
Why?
|
| Glucuronosyltransferase | 3 | 2013 | 69 | 0.110 |
Why?
|
| Liver Regeneration | 1 | 2013 | 38 | 0.110 |
Why?
|
| Mitochondria, Liver | 1 | 2013 | 31 | 0.110 |
Why?
|
| Dopamine | 1 | 2015 | 284 | 0.110 |
Why?
|
| In Vitro Techniques | 3 | 2006 | 967 | 0.110 |
Why?
|
| Altitude | 1 | 2013 | 22 | 0.110 |
Why?
|
| Cell Adhesion Molecules | 1 | 2015 | 224 | 0.110 |
Why?
|
| Bacterial Typing Techniques | 1 | 2013 | 103 | 0.110 |
Why?
|
| Decision Support Techniques | 1 | 2016 | 280 | 0.110 |
Why?
|
| Infant, Newborn | 3 | 2022 | 8118 | 0.110 |
Why?
|
| Length of Stay | 2 | 2010 | 1289 | 0.110 |
Why?
|
| Incidence | 2 | 2019 | 3052 | 0.110 |
Why?
|
| Respiratory Mucosa | 1 | 2013 | 91 | 0.100 |
Why?
|
| Infant, Premature | 2 | 2015 | 804 | 0.100 |
Why?
|
| Inflammation | 1 | 2020 | 1403 | 0.100 |
Why?
|
| Antifungal Agents | 2 | 2006 | 286 | 0.100 |
Why?
|
| Drug Dosage Calculations | 1 | 2012 | 19 | 0.100 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2012 | 75 | 0.100 |
Why?
|
| Risk | 1 | 2014 | 747 | 0.100 |
Why?
|
| Membranes, Artificial | 1 | 2012 | 27 | 0.100 |
Why?
|
| Glucuronides | 2 | 2009 | 24 | 0.100 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2011 | 49 | 0.090 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2012 | 63 | 0.090 |
Why?
|
| Rodent Diseases | 1 | 2011 | 17 | 0.090 |
Why?
|
| Carrier Proteins | 2 | 2007 | 1020 | 0.090 |
Why?
|
| Rats, Wistar | 3 | 2021 | 359 | 0.090 |
Why?
|
| Dogs | 1 | 2012 | 765 | 0.090 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2019 | 716 | 0.090 |
Why?
|
| Bordetella bronchiseptica | 1 | 2010 | 2 | 0.090 |
Why?
|
| Excipients | 1 | 2010 | 11 | 0.090 |
Why?
|
| Pharmaceutical Solutions | 1 | 2010 | 8 | 0.090 |
Why?
|
| Drug Antagonism | 2 | 2008 | 13 | 0.090 |
Why?
|
| Swine | 1 | 2014 | 1155 | 0.090 |
Why?
|
| Refrigeration | 1 | 2010 | 10 | 0.090 |
Why?
|
| Drug Stability | 1 | 2010 | 55 | 0.090 |
Why?
|
| Drug Storage | 1 | 2010 | 17 | 0.090 |
Why?
|
| Administration, Inhalation | 1 | 2011 | 179 | 0.090 |
Why?
|
| Drug Contamination | 1 | 2010 | 36 | 0.090 |
Why?
|
| Predictive Value of Tests | 3 | 2016 | 2115 | 0.090 |
Why?
|
| Fatal Outcome | 1 | 2011 | 355 | 0.090 |
Why?
|
| Flavanones | 1 | 2009 | 6 | 0.080 |
Why?
|
| Mass Spectrometry | 1 | 2011 | 326 | 0.080 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2010 | 93 | 0.080 |
Why?
|
| Quality Assurance, Health Care | 1 | 2011 | 206 | 0.080 |
Why?
|
| Drug Design | 1 | 2011 | 146 | 0.080 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 510 | 0.080 |
Why?
|
| Interleukin-8 | 1 | 2010 | 209 | 0.080 |
Why?
|
| RNA, Small Interfering | 2 | 2012 | 664 | 0.080 |
Why?
|
| Temperature | 1 | 2010 | 304 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 1006 | 0.080 |
Why?
|
| Treatment Failure | 1 | 2010 | 336 | 0.080 |
Why?
|
| Isoflavones | 2 | 2006 | 44 | 0.080 |
Why?
|
| Cyclophosphamide | 1 | 2011 | 422 | 0.080 |
Why?
|
| Ampicillin | 2 | 2017 | 58 | 0.080 |
Why?
|
| Random Allocation | 1 | 2010 | 428 | 0.080 |
Why?
|
| Colorimetry | 1 | 2008 | 15 | 0.080 |
Why?
|
| Biomass | 1 | 2008 | 17 | 0.080 |
Why?
|
| Blotting, Southern | 1 | 2008 | 215 | 0.080 |
Why?
|
| Publications | 1 | 2008 | 33 | 0.080 |
Why?
|
| Peer Review | 1 | 2008 | 40 | 0.080 |
Why?
|
| Analysis of Variance | 2 | 2008 | 1011 | 0.080 |
Why?
|
| Gene Deletion | 1 | 2012 | 792 | 0.080 |
Why?
|
| Estrogen Receptor alpha | 1 | 2012 | 454 | 0.080 |
Why?
|
| Vancomycin Resistance | 2 | 2012 | 21 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 2 | 2012 | 1259 | 0.080 |
Why?
|
| Algorithms | 2 | 2005 | 1599 | 0.070 |
Why?
|
| Confidence Intervals | 1 | 2008 | 279 | 0.070 |
Why?
|
| Respiratory System | 1 | 2008 | 95 | 0.070 |
Why?
|
| Cell Adhesion | 1 | 2008 | 318 | 0.070 |
Why?
|
| Isoelectric Focusing | 1 | 2007 | 24 | 0.070 |
Why?
|
| Spectrophotometry | 1 | 2007 | 58 | 0.070 |
Why?
|
| DNA Fingerprinting | 1 | 2007 | 107 | 0.070 |
Why?
|
| Health Care Costs | 1 | 2010 | 366 | 0.070 |
Why?
|
| Regression Analysis | 2 | 2014 | 770 | 0.070 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 1 | 2007 | 92 | 0.070 |
Why?
|
| DNA Mutational Analysis | 1 | 2009 | 790 | 0.070 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2015 | 1199 | 0.070 |
Why?
|
| Injections, Intraventricular | 1 | 2006 | 65 | 0.070 |
Why?
|
| Escherichia coli Proteins | 1 | 2009 | 303 | 0.070 |
Why?
|
| Promoter Regions, Genetic | 1 | 2010 | 1339 | 0.070 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 2007 | 107 | 0.070 |
Why?
|
| Catheter-Related Infections | 1 | 2008 | 131 | 0.070 |
Why?
|
| PubMed | 1 | 2006 | 21 | 0.070 |
Why?
|
| Cardiovascular Diseases | 1 | 2019 | 1877 | 0.070 |
Why?
|
| Injections, Spinal | 1 | 2006 | 118 | 0.070 |
Why?
|
| Logistic Models | 2 | 2008 | 1801 | 0.070 |
Why?
|
| Sequence Analysis, DNA | 2 | 2010 | 1752 | 0.070 |
Why?
|
| Stochastic Processes | 1 | 2006 | 33 | 0.070 |
Why?
|
| Sample Size | 1 | 2006 | 85 | 0.070 |
Why?
|
| Sternum | 1 | 2006 | 53 | 0.070 |
Why?
|
| Deoxycholic Acid | 1 | 2006 | 13 | 0.070 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2012 | 714 | 0.070 |
Why?
|
| Prognosis | 2 | 2014 | 4515 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2016 | 2587 | 0.070 |
Why?
|
| Cluster Analysis | 1 | 2007 | 400 | 0.070 |
Why?
|
| Ventriculostomy | 1 | 2006 | 36 | 0.060 |
Why?
|
| Amphotericin B | 1 | 2006 | 90 | 0.060 |
Why?
|
| Point Mutation | 1 | 2007 | 348 | 0.060 |
Why?
|
| Population Dynamics | 1 | 2005 | 29 | 0.060 |
Why?
|
| Porins | 1 | 2005 | 41 | 0.060 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2005 | 57 | 0.060 |
Why?
|
| Odds Ratio | 1 | 2008 | 1247 | 0.060 |
Why?
|
| Infection Control | 1 | 2006 | 160 | 0.060 |
Why?
|
| Blotting, Western | 1 | 2007 | 1101 | 0.060 |
Why?
|
| Colombia | 1 | 2024 | 48 | 0.060 |
Why?
|
| Aspergillus fumigatus | 1 | 2004 | 41 | 0.060 |
Why?
|
| Phenotype | 2 | 2013 | 4226 | 0.060 |
Why?
|
| Peptides, Cyclic | 1 | 2004 | 52 | 0.060 |
Why?
|
| Genotype | 1 | 2010 | 2533 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 1290 | 0.060 |
Why?
|
| Monobactams | 1 | 2023 | 5 | 0.060 |
Why?
|
| Nose | 1 | 2024 | 92 | 0.060 |
Why?
|
| Drug Interactions | 1 | 2004 | 253 | 0.060 |
Why?
|
| Surgical Wound Infection | 1 | 2006 | 265 | 0.060 |
Why?
|
| Biological Availability | 1 | 2003 | 129 | 0.050 |
Why?
|
| Sampling Studies | 1 | 2003 | 74 | 0.050 |
Why?
|
| Data Interpretation, Statistical | 1 | 2004 | 228 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 1 | 2006 | 501 | 0.050 |
Why?
|
| Case-Control Studies | 3 | 2019 | 3240 | 0.050 |
Why?
|
| Carbon Isotopes | 1 | 2003 | 271 | 0.050 |
Why?
|
| Whole Genome Sequencing | 1 | 2024 | 281 | 0.050 |
Why?
|
| Hospital Mortality | 1 | 2008 | 1011 | 0.050 |
Why?
|
| Statistics, Nonparametric | 1 | 2003 | 424 | 0.050 |
Why?
|
| Hospitals, Urban | 1 | 2002 | 98 | 0.050 |
Why?
|
| Enterococcus | 1 | 2002 | 32 | 0.050 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2024 | 220 | 0.050 |
Why?
|
| Emulsions | 1 | 2022 | 65 | 0.050 |
Why?
|
| Solubility | 1 | 2022 | 132 | 0.050 |
Why?
|
| Particle Size | 1 | 2022 | 115 | 0.050 |
Why?
|
| Rhodococcus equi | 1 | 2001 | 4 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2004 | 1390 | 0.050 |
Why?
|
| Actinomycetales Infections | 1 | 2001 | 12 | 0.050 |
Why?
|
| Central Nervous System | 1 | 2003 | 253 | 0.050 |
Why?
|
| Drug Delivery Systems | 1 | 2022 | 184 | 0.040 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2001 | 137 | 0.040 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2022 | 374 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2010 | 3081 | 0.040 |
Why?
|
| Community Health Nursing | 1 | 1999 | 3 | 0.040 |
Why?
|
| Neoplasms | 1 | 2014 | 2757 | 0.040 |
Why?
|
| Infant | 2 | 2014 | 12379 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 2012 | 2479 | 0.040 |
Why?
|
| Penicillins | 1 | 2000 | 154 | 0.040 |
Why?
|
| Ambulatory Care | 2 | 2016 | 378 | 0.040 |
Why?
|
| Vietnam | 1 | 2019 | 44 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2021 | 669 | 0.040 |
Why?
|
| Software | 1 | 2003 | 675 | 0.040 |
Why?
|
| Nafcillin | 1 | 2017 | 14 | 0.040 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2006 | 1099 | 0.040 |
Why?
|
| Methicillin | 1 | 2017 | 43 | 0.040 |
Why?
|
| Macaca fascicularis | 1 | 2017 | 85 | 0.040 |
Why?
|
| Glycopeptides | 1 | 2017 | 25 | 0.040 |
Why?
|
| Data Collection | 1 | 1999 | 384 | 0.040 |
Why?
|
| Salvage Therapy | 1 | 2019 | 193 | 0.030 |
Why?
|
| Genistein | 2 | 2007 | 39 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2017 | 235 | 0.030 |
Why?
|
| Azocines | 1 | 2016 | 3 | 0.030 |
Why?
|
| Mecamylamine | 1 | 2016 | 10 | 0.030 |
Why?
|
| Quinolizines | 1 | 2016 | 7 | 0.030 |
Why?
|
| Varenicline | 1 | 2016 | 14 | 0.030 |
Why?
|
| Propylthiouracil | 1 | 2016 | 9 | 0.030 |
Why?
|
| Alkaloids | 1 | 2016 | 33 | 0.030 |
Why?
|
| Nucleus Accumbens | 1 | 2016 | 54 | 0.030 |
Why?
|
| Administration, Intravesical | 1 | 2015 | 32 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2016 | 151 | 0.030 |
Why?
|
| Structure-Activity Relationship | 2 | 2007 | 569 | 0.030 |
Why?
|
| Phylogeny | 1 | 2017 | 694 | 0.030 |
Why?
|
| Intestinal Absorption | 2 | 2006 | 190 | 0.030 |
Why?
|
| Receptors, Nicotinic | 1 | 2016 | 154 | 0.030 |
Why?
|
| Linkage Disequilibrium | 1 | 2016 | 309 | 0.030 |
Why?
|
| Technetium Tc 99m Pentetate | 1 | 2014 | 9 | 0.030 |
Why?
|
| Italy | 1 | 2014 | 111 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 2014 | 151 | 0.030 |
Why?
|
| Limit of Detection | 1 | 2014 | 60 | 0.030 |
Why?
|
| Drug Therapy | 1 | 2014 | 85 | 0.030 |
Why?
|
| Acid Phosphatase | 1 | 2013 | 13 | 0.030 |
Why?
|
| Ornithine Decarboxylase | 1 | 2013 | 18 | 0.030 |
Why?
|
| Transplantation, Homologous | 1 | 2015 | 659 | 0.030 |
Why?
|
| Radiopharmaceuticals | 1 | 2014 | 155 | 0.030 |
Why?
|
| Boronic Acids | 1 | 2013 | 48 | 0.030 |
Why?
|
| Reference Standards | 1 | 2014 | 239 | 0.030 |
Why?
|
| Oxidative Phosphorylation | 1 | 2013 | 92 | 0.030 |
Why?
|
| Maxillofacial Prosthesis | 1 | 1992 | 1 | 0.030 |
Why?
|
| Hospitalization | 2 | 2012 | 1739 | 0.030 |
Why?
|
| Bilirubin | 1 | 2013 | 121 | 0.030 |
Why?
|
| Hepatectomy | 1 | 2013 | 109 | 0.030 |
Why?
|
| Adhesives | 1 | 1992 | 9 | 0.030 |
Why?
|
| Silicone Elastomers | 1 | 1992 | 35 | 0.030 |
Why?
|
| Creatine Kinase | 1 | 2012 | 54 | 0.030 |
Why?
|
| Cost Control | 1 | 2011 | 24 | 0.020 |
Why?
|
| Drug Utilization Review | 1 | 2011 | 33 | 0.020 |
Why?
|
| Organizational Innovation | 1 | 2011 | 44 | 0.020 |
Why?
|
| Cytochrome P-450 CYP1A1 | 1 | 2012 | 82 | 0.020 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2012 | 261 | 0.020 |
Why?
|
| Inpatients | 1 | 2014 | 492 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 3382 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2012 | 695 | 0.020 |
Why?
|
| Hospitals, Public | 1 | 2010 | 38 | 0.020 |
Why?
|
| Propionates | 1 | 2009 | 30 | 0.020 |
Why?
|
| Leukotriene Antagonists | 1 | 2009 | 17 | 0.020 |
Why?
|
| Dipyridamole | 1 | 2009 | 29 | 0.020 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2009 | 29 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2011 | 449 | 0.020 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2009 | 52 | 0.020 |
Why?
|
| Estradiol | 1 | 2012 | 544 | 0.020 |
Why?
|
| Biological Transport | 1 | 2009 | 347 | 0.020 |
Why?
|
| Global Health | 1 | 2013 | 546 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2010 | 715 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 2852 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2014 | 13916 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2013 | 2014 | 0.020 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2009 | 186 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2016 | 1638 | 0.020 |
Why?
|
| Patient Care Team | 1 | 2012 | 549 | 0.020 |
Why?
|
| Apigenin | 1 | 2007 | 9 | 0.020 |
Why?
|
| Caco-2 Cells | 1 | 2007 | 96 | 0.020 |
Why?
|
| Kidney Function Tests | 1 | 2008 | 126 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2007 | 236 | 0.020 |
Why?
|
| Recurrence | 1 | 2010 | 1419 | 0.020 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2007 | 184 | 0.020 |
Why?
|
| Rats, Inbred Strains | 1 | 2006 | 233 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2012 | 1702 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2007 | 408 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2011 | 518 | 0.020 |
Why?
|
| DNA, Fungal | 1 | 2006 | 75 | 0.020 |
Why?
|
| Periodicals as Topic | 1 | 2008 | 195 | 0.020 |
Why?
|
| Subcutaneous Tissue | 1 | 2005 | 15 | 0.020 |
Why?
|
| Intestines | 1 | 2009 | 570 | 0.020 |
Why?
|
| Infusions, Parenteral | 1 | 2005 | 100 | 0.020 |
Why?
|
| Perfusion | 1 | 2006 | 200 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 5050 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2012 | 3291 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 2004 | 73 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2012 | 2307 | 0.010 |
Why?
|
| Lipopeptides | 1 | 2004 | 33 | 0.010 |
Why?
|
| Echinocandins | 1 | 2004 | 44 | 0.010 |
Why?
|
| Reference Values | 1 | 2005 | 701 | 0.010 |
Why?
|
| Drug Resistance, Multiple | 1 | 2003 | 49 | 0.010 |
Why?
|
| Pneumococcal Infections | 1 | 2006 | 274 | 0.010 |
Why?
|
| Mice, Inbred ICR | 1 | 2003 | 147 | 0.010 |
Why?
|
| Coronary Artery Bypass | 1 | 2006 | 490 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2006 | 1415 | 0.010 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2006 | 429 | 0.010 |
Why?
|
| Trauma Centers | 1 | 2002 | 173 | 0.010 |
Why?
|
| Child | 1 | 2014 | 24264 | 0.010 |
Why?
|
| Tensile Strength | 1 | 1992 | 38 | 0.010 |
Why?
|
| Rotation | 1 | 1992 | 51 | 0.010 |
Why?
|
| Surface Properties | 1 | 1992 | 76 | 0.010 |
Why?
|
| Materials Testing | 1 | 1992 | 73 | 0.010 |
Why?
|
| Stress, Mechanical | 1 | 1992 | 170 | 0.010 |
Why?
|
| Skin | 1 | 1992 | 507 | 0.010 |
Why?
|